BOSTON — From 2019 to 2023, insurance covered GLP-1 receptor agonist prescriptions at a Texas hospital for less than 70% of young people with type 2 diabetes and less than 40% of those with obesity.
In addition, 44% of pediatric patients with obesity and 17% with type 2 diabetes prescribed liraglutide (Saxenda, Victoza; Novo Nordisk) discontinued the medication before reaching the approved treatment dose, according to data presented at ENDO 2024.
“We have medications that have proven to improve weight as well as type 2 diabetes control. However, getting the patient to take it as